PL3294323T3 - Wirus związany z adenowirusem do terapeutycznego dostarczania do ośrodkowego układu nerwowego - Google Patents
Wirus związany z adenowirusem do terapeutycznego dostarczania do ośrodkowego układu nerwowegoInfo
- Publication number
- PL3294323T3 PL3294323T3 PL16797013T PL16797013T PL3294323T3 PL 3294323 T3 PL3294323 T3 PL 3294323T3 PL 16797013 T PL16797013 T PL 16797013T PL 16797013 T PL16797013 T PL 16797013T PL 3294323 T3 PL3294323 T3 PL 3294323T3
- Authority
- PL
- Poland
- Prior art keywords
- nervous system
- central nervous
- therapeutic delivery
- adenovirus virus
- adenovirus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562162174P | 2015-05-15 | 2015-05-15 | |
| US201562252055P | 2015-11-06 | 2015-11-06 | |
| US201662301980P | 2016-03-01 | 2016-03-01 | |
| US201662331156P | 2016-05-03 | 2016-05-03 | |
| PCT/US2016/032392 WO2016187017A1 (en) | 2015-05-15 | 2016-05-13 | Adeno-associated for therapeutic delivery to central nervous system |
| EP16797013.6A EP3294323B1 (en) | 2015-05-15 | 2016-05-13 | Adeno-associated virus for therapeutic delivery to central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3294323T3 true PL3294323T3 (pl) | 2022-06-20 |
Family
ID=57320277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16797013T PL3294323T3 (pl) | 2015-05-15 | 2016-05-13 | Wirus związany z adenowirusem do terapeutycznego dostarczania do ośrodkowego układu nerwowego |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20180289839A1 (pl) |
| EP (2) | EP4000631A1 (pl) |
| JP (4) | JP2018515615A (pl) |
| KR (3) | KR20220082100A (pl) |
| CN (1) | CN108367055A (pl) |
| AU (2) | AU2016263119B2 (pl) |
| BR (1) | BR112017024519A2 (pl) |
| CA (1) | CA2986252A1 (pl) |
| CY (1) | CY1125229T1 (pl) |
| DK (1) | DK3294323T3 (pl) |
| ES (1) | ES2901766T3 (pl) |
| HK (1) | HK1256341A1 (pl) |
| HR (1) | HRP20220050T1 (pl) |
| HU (1) | HUE057795T2 (pl) |
| LT (1) | LT3294323T (pl) |
| MX (2) | MX2017014443A (pl) |
| PL (1) | PL3294323T3 (pl) |
| PT (1) | PT3294323T (pl) |
| RS (1) | RS63927B1 (pl) |
| RU (1) | RU2751952C2 (pl) |
| SI (1) | SI3294323T1 (pl) |
| SM (1) | SMT202200022T1 (pl) |
| WO (1) | WO2016187017A1 (pl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2786253T3 (es) | 2013-03-14 | 2020-10-09 | Immusoft Corp | Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g |
| BR112015021036A2 (pt) | 2013-03-15 | 2017-10-10 | Univ Pennsylvania | composições e métodos para tratar mps1 |
| JP2016523835A (ja) * | 2013-05-15 | 2016-08-12 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入 |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| KR20220082100A (ko) * | 2015-05-15 | 2022-06-16 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 중추 신경계로의 아데노-연관 치료적 전달 |
| MA43968A (fr) | 2016-02-03 | 2018-12-12 | Univ Pennsylvania | Thérapie génique pour traiter la mucopolysaccharidose de type i |
| US11253612B2 (en) | 2016-04-15 | 2022-02-22 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type II |
| IL309808B2 (en) * | 2016-11-15 | 2025-04-01 | Univ Minnesota | Method for improving neurological function in MPSI and MPSII and other neurological disorders |
| KR20240093919A (ko) | 2017-04-14 | 2024-06-24 | 리젠엑스바이오 인크. | 인간 뉴런 또는 신경교 세포에 의해 생성된 재조합 인간 이두로네이트-2 설파타제(ids)를 이용한 뮤코다당증 ii형의 치료 |
| JP2020517692A (ja) * | 2017-04-27 | 2020-06-18 | イミュソフト コーポレーション | 治療剤のin vivo送達のためのB細胞およびその投薬量 |
| CA3068328A1 (en) * | 2017-07-06 | 2019-01-10 | The Trustees Of The University Of Pennsylvania | Aav9-mediated gene therapy for treating mucopolysaccharidosis type i |
| EP3684938A1 (en) * | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| CN111542549A (zh) | 2017-10-03 | 2020-08-14 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| MX2020004005A (es) | 2017-10-03 | 2020-10-05 | Prevail Therapeutics Inc | Terapias genicas para los trastornos lisosomales. |
| EP3692158A4 (en) | 2017-10-03 | 2021-08-04 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| EA202091352A1 (ru) * | 2017-11-30 | 2020-08-27 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Генотерапия мукополисахаридоза iiib |
| US11738093B2 (en) | 2018-04-09 | 2023-08-29 | Hope For Annabel | AAV-mediated delivery of ATP1A3 genes to central nervous system |
| IL280198B2 (en) * | 2018-07-18 | 2026-01-01 | Regenxbio Inc | Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus) |
| EP3931337A1 (en) * | 2019-02-26 | 2022-01-05 | The Trustees of The University of Pennsylvania | Compositions useful in treatment of krabbe disease |
| EA202192328A1 (ru) * | 2019-03-22 | 2022-02-21 | Раш Юниверсити Медикал Сентер | Комбинация назальной доставки генов и пероральной доставки коричной кислоты, олеамида или гемфиброзила для лечения лизосомных болезней накопления |
| JP7664848B2 (ja) | 2019-04-10 | 2025-04-18 | プリベイル セラピューティクス,インコーポレーテッド | リソソーム障害のための遺伝子療法 |
| JP7715640B2 (ja) * | 2019-05-03 | 2025-07-30 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異染性白質ジストロフィーの治療に有用な組成物 |
| PE20220233A1 (es) * | 2019-06-10 | 2022-02-07 | Homology Medicines Inc | Composiciones de virus adenoasociados para la transferencia del gen de arsa y metodos de uso de las mismas |
| JP7697943B2 (ja) * | 2019-10-23 | 2025-06-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 導入遺伝子発現のdrg特異的低減のための組成物 |
| KR20220112283A (ko) | 2019-12-10 | 2022-08-10 | 다케다 야쿠힌 고교 가부시키가이샤 | Hunter 질환 치료용 아데노-연합된 바이러스 벡터 |
| CN116157527A (zh) * | 2020-08-10 | 2023-05-23 | 普利维尔治疗公司 | 用于溶酶体病症的基因疗法 |
| AU2021325891A1 (en) * | 2020-08-10 | 2023-04-06 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative disorders |
| WO2022121860A1 (en) * | 2020-12-07 | 2022-06-16 | East China University Of Science And Technology | Methods and kits for inducing immunotolerance to gene delivering target vehicle |
| MX2023008826A (es) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Terapia génica para lipofuscinosis neuronal ceroidea. |
| AU2022221284A1 (en) | 2021-02-10 | 2023-08-17 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) |
| WO2022212616A1 (en) * | 2021-04-01 | 2022-10-06 | The University Of North Carolina At Chapel Hill | Aav-ids vectors for treatment of mucopolysaccharidosis ii |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| EP0733103B1 (en) | 1993-11-09 | 2004-03-03 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
| DE69433922T2 (de) | 1993-11-09 | 2005-07-28 | Medical College Of Ohio, Toledo | Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren |
| WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| US5656785A (en) | 1995-08-07 | 1997-08-12 | The Charles Stark Draper Laboratory, Inc. | Micromechanical contact load force sensor for sensing magnitude and distribution of loads and tool employing micromechanical contact load force sensor |
| ATE355645T1 (de) | 1996-11-19 | 2006-03-15 | Surgx Corp | Schutzvorrichtung gegen transiente spannungen und verfahren zu deren herstellung |
| CA2270285A1 (en) | 1996-12-18 | 1998-06-25 | Targeted Genetics Corporation | Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors |
| EP1915986A1 (en) | 2006-10-23 | 2008-04-30 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH | Lipid growth factor formulations |
| EP2396343B1 (en) * | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| EP2394667A1 (en) * | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
| KR20130043165A (ko) * | 2010-06-25 | 2013-04-29 | 샤이어 휴먼 지네틱 테라피즈 인크. | 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들 |
| ES2745470T3 (es) * | 2011-03-31 | 2020-03-02 | Univ Iowa Res Found | Partícula de AAV2 que comprende una proteína de la cápside de AAV2 y un vector que comprende un ácido nucleico que codifica una tripeptidilo peptidasa 1 (TPP1) para el tratamiento de lipofuscinosis ceroide infantil tardía (LINCL) en un mamífero no roedor mediante inyección intraventricular o administración icv |
| US8609088B2 (en) * | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
| US20130039888A1 (en) * | 2011-06-08 | 2013-02-14 | Nationwide Children's Hospital Inc. | Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders |
| US9222105B2 (en) * | 2011-10-27 | 2015-12-29 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the HPRT locus |
| JP2016523835A (ja) * | 2013-05-15 | 2016-08-12 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入 |
| RU2664471C2 (ru) * | 2013-07-26 | 2018-08-17 | Юниверсити Оф Айова Рисерч Фаундейшн | Способы и композиции для лечения болезней мозга |
| KR20220082100A (ko) * | 2015-05-15 | 2022-06-16 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 중추 신경계로의 아데노-연관 치료적 전달 |
| IL309808B2 (en) * | 2016-11-15 | 2025-04-01 | Univ Minnesota | Method for improving neurological function in MPSI and MPSII and other neurological disorders |
| AU2022221284A1 (en) * | 2021-02-10 | 2023-08-17 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) |
-
2016
- 2016-05-13 KR KR1020227018782A patent/KR20220082100A/ko not_active Ceased
- 2016-05-13 HR HRP20220050TT patent/HRP20220050T1/hr unknown
- 2016-05-13 PT PT167970136T patent/PT3294323T/pt unknown
- 2016-05-13 KR KR1020177036062A patent/KR102406615B1/ko active Active
- 2016-05-13 LT LTEPPCT/US2016/032392T patent/LT3294323T/lt unknown
- 2016-05-13 MX MX2017014443A patent/MX2017014443A/es unknown
- 2016-05-13 WO PCT/US2016/032392 patent/WO2016187017A1/en not_active Ceased
- 2016-05-13 BR BR112017024519-1A patent/BR112017024519A2/en not_active Application Discontinuation
- 2016-05-13 JP JP2018511353A patent/JP2018515615A/ja active Pending
- 2016-05-13 SI SI201631430T patent/SI3294323T1/sl unknown
- 2016-05-13 HU HUE16797013A patent/HUE057795T2/hu unknown
- 2016-05-13 SM SM20220022T patent/SMT202200022T1/it unknown
- 2016-05-13 ES ES16797013T patent/ES2901766T3/es active Active
- 2016-05-13 DK DK16797013.6T patent/DK3294323T3/da active
- 2016-05-13 PL PL16797013T patent/PL3294323T3/pl unknown
- 2016-05-13 EP EP21201643.0A patent/EP4000631A1/en not_active Withdrawn
- 2016-05-13 RU RU2017143640A patent/RU2751952C2/ru active
- 2016-05-13 US US15/574,432 patent/US20180289839A1/en not_active Abandoned
- 2016-05-13 CN CN201680037625.2A patent/CN108367055A/zh active Pending
- 2016-05-13 AU AU2016263119A patent/AU2016263119B2/en active Active
- 2016-05-13 RS RS20211570A patent/RS63927B1/sr unknown
- 2016-05-13 CA CA2986252A patent/CA2986252A1/en active Pending
- 2016-05-13 KR KR1020257032548A patent/KR20250150167A/ko active Pending
- 2016-05-13 HK HK18115428.0A patent/HK1256341A1/zh unknown
- 2016-05-13 EP EP16797013.6A patent/EP3294323B1/en active Active
-
2017
- 2017-11-10 MX MX2022012524A patent/MX2022012524A/es unknown
- 2017-11-15 US US15/813,908 patent/US20180071373A1/en not_active Abandoned
-
2021
- 2021-06-10 US US17/344,308 patent/US20210369871A1/en not_active Abandoned
- 2021-07-05 JP JP2021111318A patent/JP2021167332A/ja not_active Withdrawn
- 2021-11-12 AU AU2021266344A patent/AU2021266344B2/en active Active
-
2022
- 2022-01-12 US US17/574,118 patent/US20220211875A1/en not_active Abandoned
- 2022-01-13 CY CY20221100032T patent/CY1125229T1/el unknown
- 2022-07-19 JP JP2022114547A patent/JP2022137261A/ja active Pending
-
2023
- 2023-01-05 US US18/150,740 patent/US20230226225A1/en not_active Abandoned
-
2024
- 2024-07-17 JP JP2024113975A patent/JP2024147704A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290823A (en) | Pharmaceutical compositions for combination therapy | |
| LT3294323T (lt) | Adenoasocijuotas virusas, skirtas terapiniam pristatymui į centrinę nervų sistemą | |
| DK3265421T3 (da) | Doseringssystem | |
| DK3328880T3 (da) | Terapeutiske midler | |
| EP3291824C0 (en) | ANTIMICROBIAL THERAPY | |
| EP3314027A4 (en) | THERAPEUTIC OLIGONUCLEOTIDES | |
| EP3368656A4 (en) | TARGETED CANCER THERAPY | |
| DK3139986T3 (da) | System til administration af terapeutisk gas | |
| LT3253865T (lt) | Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą | |
| MA40764A (fr) | Agent thérapeutique induisant une cytotoxicité | |
| GB201500463D0 (en) | Therapeutic molecules | |
| EP3389589C0 (en) | MEDICAL DELIVERY DEVICE | |
| GB201500461D0 (en) | Therapeutic molecules | |
| DK3258938T3 (da) | Phenothiazinanaloger som mitokondrie terapeutiske midler | |
| IL257845A (en) | In-line nasal delivery device | |
| DK3199161T3 (da) | Farmaceutisk præparat | |
| DK3310800T3 (da) | Leveringssystem til styret lægemiddelfrigivelse | |
| EP3213736C0 (en) | DRUG DELIVERY DEVICE | |
| DK3363428T3 (da) | Perfusionsdoseringsform | |
| DK3288955T3 (da) | Bortezomib-baseret afgivelsessystem | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| EP3246047C0 (en) | COMBINATION MEDICATION | |
| EP3244868C0 (en) | DRUG DELIVERY DEVICES | |
| DK3393478T3 (da) | Kombinationsterapi | |
| EP4233950C0 (en) | NASAL ADMINISTRATION |